Biolab launches Biolab & Co. brand to consolidate ecosystem and accelerate global expansion

With revenues of R$ 3.2 billion by 2025, the group adopts a "house of brands" model and unifies business units under a new visual identity

Biolab Farmacêutica has announced the launch of Biolab & Co., a new institutional brand that now encompasses the group's entire ecosystem. Under the house of brands model, the initiative aims to unify the corporate architecture and strengthen communication with its various audiences - from the medical profession and patients to the veterinary sector and international partners.

Biolab & Co. currently comprises six strategic business units: Biolab Pharmaceuticals (leader in cardiology), Biolab Generics, Avert Biolab Animal Health, Avert Human Health, Pet Nutrition and the Canadian Exzell Pharma.

New Identity: Trust and Humanization

The transition to Biolab & Co. brings a new visual identity developed by the AR Propaganda agency. The project adopts navy blue as the master color, symbolizing the solidity needed for the B2B market and trust for the end consumer. The communication also takes on a more human and "multi-species" tone, featuring real people and pets to reflect the diversity of the portfolio.

“The brand reflects the maturity of our group. In Brazil, we are strengthening our competitiveness, while on the international stage, a unique identity facilitates entry into new countries and accelerates strategic partnerships,” says Fabio Amorosino, CEO of Biolab & Co.

Robust Structure and Manufacturing Expansion

The group ended 2025 with significant results and an infrastructure prepared for the growth projected for 2026:

Revenue: R$ 3.2 billion in 2025.

Sales force: 1,800 professionals making 320,000 medical visits a month.

Production Capacity: In addition to the three factories in São Paulo, the group is expanding its operations with the new complex in Pouso Alegre (MG), with 100,000 m² and capacity for 400 million units of medicines per year.

Innovation: Two RD&I centers in Brazil and its own center in Canada, making it the only Brazilian pharmaceutical company with a research center outside the country.

Governance and Global Strategy

Biolab & Co. maintains the tagline “Viva a Evolução!” (Long Live Evolution!), reinforcing the scientific DNA of the company founded by brothers Cleiton and Paulo de Castro Marques with Dante Alario Júnior. The strengthening of the brand also goes hand in hand with improved corporate governance.

The group's advisory board includes important names in the market, such as Cássio Casseb (ex-BB), João Bezerra Leite (ex-Itaú), Paulo Gandolfi (CEO of 3M Brasil) and, more recently, Adriano Treve (ex-Roche), who has taken over as international advisor to support the entry into new markets in Central America, Saudi Arabia and other strategic territories.

For Tati Marques, the group's communications manager, the moment is one of integration. "Biolab & Co. combines the tradition built up by its founders with the modernization needed for a global company that delivers trust and innovation on all its fronts," she concludes.

Check out the article on the website: Biolab launches Biolab & Co. brand to consolidate ecosystem and accelerate global expansion